Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

INTRODUCTION: The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer’s disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Alzheimers Res Ther
Auteurs principaux: Doody, Rachelle S, Raman, Rema, Sperling, Reisa A, Seimers, Eric, Sethuraman, Gopalan, Mohs, Richard, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Sun, Xiaoying, Ernstrom, Karin, Thomas, Ronald G, Aisen, Paul S
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2015
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4461930/
https://ncbi.nlm.nih.gov/pubmed/26064192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-015-0121-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires